OBJECTIVES: To conduct a cost-consequence analysis of the treatment of subependymal giant cell astrocytoma (SEGA) secondary to tuberous sclerosis complex (TSC) with everolimus under the Brazilian public healthcare system (SUS) and societal perspectives. METHODS: A cost-consequence analysis was developed to compare the treatment of SEGA secondary to TSC with everolimus and current treatment options, based on the Phase II trial of everolimus in the indication. Population included patients above 3-years of age. Direct medical costs were estimated from the perspective of the SUS, while direct medical and productivity costs were estimated from a societal perspective. Model inputs for SEGA growth, hydrocephalus and seizure controls were based on the trial results. Use of resources and unit costs were obtained from the national and international literature and administrative databases.  Analysis included costs for managing adverse events on everolimus treatment. Costs are expressed in 2011 Reals. Results are presented in terms of incremental cost per patient with everolimus, considering scenarios with and without seizure control. Time horizon was set in two years and no discount was applied. Univariate sensitivity analysis was performed. RESULTS: The incremental cost of treatment with everolimus was R$49.790/patient and R$40.131/patient from the perspectives of SUS and society, respectively.  Patients treated with everolimus did not experience complications of SEGA growth, and did not undergo surgery to remove the SEGA.  If improved seizure control is considered, the incremental cost is reduced to R$48.949/patient and R$39.290/patient from SUS and societal perspectives, respectively. Results were most sensitive to drug cost and average dose. CONCLUSIONS: The incremental cost per patient with everolimus in SEGA/TSC can be used as a simple instrument in the HTA process in Brazil, indicating value for money in the comparison of current invasive interventions with novel drug therapy affecting both patients and their caregivers.